Combination therapy when metformin is not an option for type 2 diabetes

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Metformin is a first-line therapy for type 2 diabetes mellitus (T2DM), but some patients cannot tolerate it.
• Lack of consensus exists regarding optimal combination therapies for T2DM patients who cannot use metformin.
• This review focuses on non-metformin based combination therapies for T2DM management.

Purpose of the Study:

• To summarize existing data on non-metformin based combination therapies for T2DM.
• To provide insights into treatment options for patients intolerant to metformin.
• To inform clinical decision-making for individualized T2DM management.

Main Methods:

• Literature search of PubMed (January 1990 to August 2014) using terms for newer drug therapies and combination treatments.
• Inclusion of Clinical Trials, Meta-Analyses, and English-language studies.
• Focus on multicenter, randomized controlled trials of non-metformin combination therapies from the past 5 years, including US and multinational populations.

Main Results:

• Data on non-metformin combinations are less extensive than metformin combinations.
• Incretin-based combinations (GLP-1 RAs, DPP-4 inhibitors) with sulfonylureas, TZD, or insulin show superior glucose lowering compared to monotherapy.
• Newer combinations of SGLT2 inhibitors and DPP-4 inhibitors show promise, with significant A1C reduction and weight loss without increased hypoglycemia risk.

Conclusions:

• Selecting T2DM combination therapy requires balancing clinical efficacy against risks like weight gain and hypoglycemia.
• Individualized treatment strategies are crucial for patients with T2DM for whom metformin is contraindicated.
• Non-metformin combination therapies, particularly those involving incretins and SGLT2 inhibitors, offer viable alternatives for glycemic control.